Gumokimab (AK 111) is a humanized monoclonal antibody designed to specifically target interleukin-17A (IL-17A). it functions by competitively inhibiting the binding of IL-17A to its cognate receptor, thereby blocking downstream pro-inflammatory signaling, Gumokimab is a candidate for therapeutic research in psoriasis and ankylosing spondylitis.
Purity:
95.10%
CAS Number:
[2428381-52-4]
Target:
IL Receptor|||Interleukin
* VAT and and shipping costs not included. Errors and price changes excepted
